Table II.
Side effects reported as reasons for discontinuation of BPO, azelaic acid, adapalene, A/BPO and Clin-RA
| ∗ | BPO (n = 93) |
Azelaic acid (n = 246) | Adapalene (n = 254) | A/BPO (n = 264) | Clin-RA (n = 303) | All therapies confounded (n = 1160) |
|---|---|---|---|---|---|---|
| Side effect as reason for discontinuation, n (%) | ||||||
| Dryness | 8 (8.6) | 3 (1.2) | 7 (2.8) | 6 (2.3) | 11 (3.6) | 35 (3.0) |
| Irritation | 5 (5.3) | 5 (2) | 11 (4.3) | 14 (5.3) | 7 (2.3) | 42 (3.6) |
| Eczema | 2 (2.1) | 0 (0) | 2 (0.8) | 7 (2.7) | 2 (0.7) | 13 (1.1) |
| Acne exacerbation | 0 (0) | 0 (0) | 1 (0.4) | 0 (0) | 0 (0) | 1 (∼0) |
BPO, Benzoyl peroxide; A/BPO, fixed combination of adapalene 0.1% and BPO 2.5%; Clin-RA, fixed combination of clindamycin 1.2% and tretinoin 0.025% gel.
∗
Values are given as n (%) unless otherwise indicated.